Otonomy

United States
Wonewoc, Wisconsin, United States, 92121

Company profile

Otonomy company profile

Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes, and from these, three product candidates have been advanced into development.

Business identity

Contact email
[email protected]
Phone number
+1 8587687809
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0+
Founded
2008-01-01, Year

Headquarters

Postal code
92121
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
10
Total equity funding
$498M
Last funding
Post IPO Equity / $34.7M / 2021-04-07
Last equity funding
Post IPO Equity / $34.7M
Investors
12
Lead investors
4
Founders
3
Articles
50
Exited on
2014-08-14

Founders and investors

Founders

Allen F. RyanJay LichterJeffrey Harris

Lead investors

Avalon VenturesNovo VenturesOrbiMedRiverVest

Investors

Ally Bridge GroupAvalon VenturesOrbiMedOUP (Osage University Partners)Perceptive Advisors